Janus kinase inhibitors therapy in idiopathic inflammatory myopathies: a case series
Authors' conclusion
JAKi therapy appears to be clinically effective, well tolerated, and safe in patients with refractory IIM, with a particular benefit in ILD.
Study context
- Population
- Adult patients with refractory idiopathic inflammatory myopathies (IIM) treated with Janus kinase inhibitors (JAKi) at a single centre; ASyS most common subtype (n=5, 50%)6 female
- Participants
- 10 patients
- Exposure
- Before vs after JAKi therapy
- JAKin = 10
- Outcome
- Manual muscle test 8 score, baseline vs after therapy
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
- MMT8 at baseline, median (IQR 25.5)
- 136
- MMT8 after therapy, median (IQR 8)
- 147
- Statistically significant increase
- p<0.05
Observational data: associations, not effects.
Further findings
Daily corticosteroid dose
- Median daily dose before therapy
- 10mg
- Median daily dose after therapy
- 2.5mg
- Statistically significant reduction
- P < 0.05
- Patients who discontinued corticosteroids
- 4
DLCO in patients with interstitial lung disease (ILD)
- DLCO before therapy (IQR 19.31)
- 68.33%
- DLCO after therapy (IQR 7.27)
- 93%
- Significant improvement
- P < 0.01
- Six patients with ILD
Serum inflammatory markers, creatine kinase, FEV1, FVC
- No significant changes
Original publication
Janus kinase inhibitors therapy in idiopathic inflammatory myopathies: a case series. Clin Exp Rheumatol. Published 29 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →